Novel blood‐based proteomic signatures across multiple neurodegenerative diseases

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: 21(3)

Published: March 1, 2025

Abstract INTRODUCTION Blood‐based biomarkers have the potential to support early and accurate diagnoses of neurodegenerative diseases, which are sensitive molecular pathology predictive outcome. We evaluated a novel multiplex proteomic method in people with diverse diseases. METHODS Serum from Alzheimer's disease ( N = 36), Lewy body dementia 34), frontotemporal progressive supranuclear palsy 36) age‐matched controls 30) was analyzed nucleic acid linked immuno‐sandwich assay (NULISA) central nervous system panel (≈ 120 analytes) inflammation (250 analytes). Biomarkers were compared across groups included as predictors survival. RESULTS The NULISA panels demonstrated high sensitivity reliability for detecting multiple disorders. There condition‐specific biomarkers, while neurofilament light chain, corticotropin‐releasing hormone, CD276, data‐driven pattern significant transdiagnostic outcome predictors. DISCUSSION approach supports differential diagnosis target identification, prognostically informative dementia‐related biomarkers. Highlights tested technology serum samples. results single molecule array (Simoa) plasma assays phosphorylated tau (p‐tau)217, p‐tau231, chain (NfL), glial fibrillary acidic protein, finding strong correlations. Increased levels NfL identified all patient most elevated (FTD) (PSP) cohorts, p‐tau epitopes markers patients (AD) dementia. Patients FTD PSP showed upregulation many markers, AD. found NfL, immune signatures clinical outcomes (survival rates).

Language: Английский

Advances in blood‐based phosphorylated tau protein biomarkers and their detection technology for Alzheimer's disease

View, Journal Year: 2025, Volume and Issue: unknown

Published: May 12, 2025

Abstract Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized primarily by memory loss and impaired cognitive function. With the aging world population, incidence of AD rising, imposing substantial medical economic burdens on society. Current diagnostic methods for predominantly rely imaging studies cerebrospinal fluid analysis, which has limitations such as complex operation high costs. Therefore, development minimally invasive, convenient, accessible blood‐based biomarkers become research hotspot. Phosphorylated tau protein (p‐tau) plays crucial role in AD, its abnormal phosphorylation closely related to pathogenesis disease. This paper highlights potential applications three specific phosphorylated proteins—p‐tau217, p‐tau181, p‐tau231—in early diagnosis, differential progression monitoring aiming provide reference future clinical applications. Furthermore, reviews advancements various ultrasensitive detection technologies p‐tau measurement. The application these significantly enhanced sensitivity specificity detection, making it feasible detect low concentrations blood proteins, thereby advancing diagnosis AD.

Language: Английский